EpiSLS, A Revolutionary Medical Device Company

Founded by Dr. Parker Martin, epiSLS provides health care providers a new way to assess allergies and improve patient outcomes. EpiSLS is rooted in curiosity, determination and innovation after an unacceptable observation Dr. Martin noticed during his clinical rotations – that patients were receiving inferior, second-line treatments due to avoidance of suspicious allergies.

Dr. Martin grew obsessed in finding a way that patients could receive an allergy evaluation in an acute setting that could save them from preventable morbidity of misdiagnosed allergies. Digging deep into research, gathering data, and creating the prototype, epiSLS came into existence as a better allergy solution that outperforms the current skin prick test. Reduced errors, faster results, and accessibility to ALL patients epiSLS provides a rapid, safe, and effective platform for allergy de-labeling with the potential to reduce patient morbidity and mortality.

Our leaders

Learn more about the team that is leading this breakthrough development program.

Parker Martin
Parker Martin, MD

Lead for Technology and Medicine

Cory Cooney
Cory Cooney

Lead for Business Development and Strategy


Explore our resource library that includes case studies, articles, news from sources featuring epiSLS, and much more.

Heartland challenge

Student Startup Teams to Compete for $110,000 Cash Prize Pool in U of A’s Heartland Challenge

University of Arkansas

Rice University

Rice University’s student startup competition names 42 teams to compete for over $1 million in prizes

Innovation Map

Parker Martin

2021 Michigan Business Challenge Spotlight – EpiSLS

University of Michigan

ideabounce logo

These 14 Startup Ideas Made The Cut For WashU Olin’s BIG IdeaBounce $50K Top Prize

Poets & Quants

We are innovators looking for initiators.

We consider ourselves to be excellent at what we do, and we want to partner with others who are dedicated to also changing the face of healthcare. So, if you consider yourself to be that institutor, whether that’s an investor or a healthcare professional dedicated to improving patient care, then we should talk. We are just a conversation away from a great partnership.